A Novel Evaluation System of Psoriasis Curative Effect Based on Bayesian Maximum Entropy Weight Self-Learning and Extended Set Pair Analysis

Table 1

The characteristics of the patients and the indexes.

Characteristics	n or means	Percentages or stds	Minimums	Maximums
Male	59	59%	—	—
Ages, yrs	45.04	10.65	21	65
PASI	7.91	2.96	1.30	17.60
BSA (%)	9.57	2.84	3.00	17.00
SCC-Ag (ng/mL)	20.94	28.78	1.17	143.69
TNF-α (pg/mL)	9.38	4.49	3.70	41.70
C3 (g/L)	0.91	0.20	1.71	0.48
C4 (g/L)	0.47	2.38	0.13	24.00
IL-23 (pg/mL)	912.43	210.94	509.99	1446.99
IL-22 (pg/mL)	5.73	3.96	2.62	27.93
IL-17 (pg/mL)	5.07	1.77	1.93	9.11
IL-10 (pg/mL)	4.77	0.86	2.90	7.90
DLQI	5.58	3.18	0	15.00
SAS	36.75	9.13	25.00	68.75
SDS	32.44	10.10	25.00	80.00
XQ	16.20	9.31	0	43.00
CCS	9.74	4.97	0	21.00
PSQI	9.28	5.67	0	21.00

Stds, standard deviations; PASI, psoriasis area and severity index; BSA, body surface area; SCC-Ag, squamous cell carcinoma antigen; TNF-α, tumor necrosis factor-α; C3, complement 3; C4, complement 4; IL, interleukin; DLQI, Dermatology Life Quality Index; SAS, Self-Rating Anxiety Scale; SDS, Self-Rating Depression Scale; XQ, Xerostomia Questionnaire; CCS, Cleveland Clinic Score; PSQI, Pittsburgh Sleep Quality Index.